CLUSTER
Lewis Base Activation of Lewis Acids
2415
NMR (125 MHz, CDCl3): d = 204.09, 155.41, 142.20, 141.71,
127.12, 110.24, 106.48, 66.54, 42.84, 38.54, 26.03. [a]D24 +3.80° (c
1.0, EtOH). SFC: (R)-7 tR 5.73 min (96.0%); (S)-7 tR 6.63 min
(4.0%) (AD column, 150 bar, 3.0 mL/min, 2.5% MeOH). Anal.
Calcd for C13H18O3 (222.28): C, 79.24%; H, 8.16%. Found: C,
69.89%; H, 8.20%.
7.57–7.50 (m, 3 H), 7.23 (dt, J = 10.3, 1.8 Hz, 1 H), 6.08 (dd,
J = 10.3, 2.2 Hz, 1 H), 5.38 (d, J = 6.6 Hz, 1 H), 3.06–3.01 (m, 1 H),
2.48 (dt, J = 16.8, 4.2 Hz, 1 H), 2.23 (ddd, J = 16.8, 13.4, 5.1 Hz, 1
H), 2.21 (br s, 1 H), 1.99–1.91 (m, 1 H), 1.84–1.80 (m, 1 H). 13C
NMR (125 MHz, CDCl3): d = 200.04, 151.43, 137.77, 133.83,
130.36, 129.83, 129.08, 128.50, 126.23, 125.70, 125.33, 125.25,
24
124.01, 122.86, 73.35, 42.77, 36.87, 26.51. [a]D +89.08 (c 0.90,
(–)-(R)-7-Hydroxy-2,2-dimethyl-7-(2-thienyl)-4-hepten-3-one
(9).
EtOH). SFC: (4S,7S)-15 tR 2.50 min (5.0%); (4R,7R)-15 tR 5.08 min
(95.0%) (OJ column, 150 bar, 4.0 mL/min, 20.0% MeOH). HRMS
(ES+) m/z calcd for C17H17O2: 253.1229; found: 253.1244.
1H NMR (500 MHz, CDCl3): d = 7.27–7.25 (m, 1 H), 6.99–6.93 (m,
2 H), 6.89 (dt, J = 15.4, 7.4 Hz, 1 H), 6.58 (dt, J = 15.1, 1.5 Hz, 1
H), 5.09 (dd, J = 7.0, 6.1 Hz, 1 H), 2.82–2.71 (m, 2 H), 2.12 (br s, 1
H), 1.13 (s, 9 H). 13C NMR (125 MHz, CDCl3): d = 204.25, 147.35,
141.92, 127.21, 126.68, 124.79, 123.97, 66.98, 42.83, 42.21, 26.00.
[a]D24 –5.26 (c 1.00, EtOH). SFC: (R)-7 tR 5.63 min (94.0%); (S)-7
tR 6.63 min (4.0%) (AD column, 125 bar, 2.75 mL/min, 5.0%
MeOH). Anal. Calcd for C13H18O2S1 (238.35): C, 65.51%; H,
7.61%. Found: C, 65.30%; H, 7.66%.
(+)-(4R,7R)-4-[Hydroxy-(3-phenylpropenyl)]-2-cyclohexen-1-
one (anti-16).
1H NMR (500 MHz, CDCl3): d = 7.41 (d, J = 7.8 Hz, 2 H), 7.34 (t,
J = 7.3 Hz, 2 H), 7.30–7.27 (m, J = 7.3, 1.2 Hz, 1 H), 7.16 (ddd,
J = 10.3, 2.3, 1.6 Hz, 1 H), 6.67 (d, J = 15.9 Hz, 1 H), 6.26 (dd,
J = 15.9, 6.8 Hz, 1 H), 6.10 (ddd, J = 10.3, 2.4, 0.7 Hz, 1 H), 4.23
(t, J = 6.8 Hz, 1 H), 2.69–2.63 (m, 1 H), 2.55 (dt, J = 16.8, 4.2 Hz,
1 H), 2.39 (ddd, J = 16.8, 13.2, 5.0 Hz, 1 H), 2.14–2.08 (m, 1 H),
1.90–1.82 (m, 1 H), 1.71 (br s, 1 H). 13C NMR (125 MHz, CDCl3):
d = 199.84, 151.13, 136.00, 132.27, 130.19, 129.56, 128.66, 128.08,
(–)-(R)-7-Hydroxy-2,2-dimethyl-9-phenyl-4-nonen-8-yn-3-one
(10).
1H NMR (500 MHz, CDCl3): d = 7.43–7.41 (m, 2 H), 7.35–7.29 (m,
3 H), 7.02 (dt, J = 15.4, 7.5 Hz, 1 H), 6.69 (dt, J = 15.4, 1.2 Hz, 1
H), 4.75 (t, J = 6.1 Hz, 1 H), 2.73 (dt, J = 6.1, 1.2 Hz, 2 H), 1.65 (br
s, 1 H), 1.16 (s, 9 H). 13C NMR (125 MHz, CDCl3): d = 204.08,
141.11, 131.70, 128.61, 128.30, 127.52, 122.20, 88.76, 85.84,
61.63, 42.89, 40.72, 26.07. [a]D24 –15.96 (c 0.99, EtOH). SFC: (R)-
7 tR 1.90 min (84.0%); (S)-7 tR 3.60 min (16.0%) (OD column, 125
bar, 3.00 mL/min, 17.5% MeOH). Anal. Calcd for C17H20O2
(256.34): C, 79.65%; H, 7.86%. Found: C, 79.68%; H, 7.72%.
126.51, 75.04, 42.25, 36.86, 25.47. [a]D +52.73 (c 1.43, EtOH).
24
SFC: (4R,7R)-16 tR 4.91 min (84.5%); (4S,7S)-16 tR 6.47 min
(15.5%) (OD column, 125 bar, 3.0 mL/min, 20.0% MeOH). Anal.
Calcd for C15H16O2 (228.29): C, 78.92%; H, 7.06%. Found: C,
79.03%; H, 7.06%.
(+)-(4R,7R)-4-[Hydroxy-(2-furanyl)methyl]-2-cyclohexen-1-
one (anti-17).
1H NMR (500 MHz, CDCl3): d = 7.41 (t, J = 1.5 Hz, 2 H), 7.35 (t,
J = 2.0 Hz, 1 H), 6.38 (dd, J = 3.2, 2.0 Hz, 1 H), 6.33 (d, J = 3.2 Hz,
1 H), 6.10 (dd, J = 10.3, 2.4 Hz, 1 H), 4.64 (dd, J = 7.5, 5.0 Hz, 1
H), 2.98–2.94 (m, 1 H), 2.51 (dt, J = 16.8, 4.4 Hz, 1 H), 2.38 (ddd,
J = 16.8, 12.9, 5.1 Hz, 1 H), 2.03 (d, J = 5.1 Hz, 1 H), 1.90–1.74 (m,
2 H). 13C NMR (125 MHz, CDCl3): d = 199.84, 154.36, 151.05,
General Procedure for the Aldol Reaction of 12.
(+)-(4R,7R)-4-(Hydroxyphenylmethyl)-2-cyclohexen-1-one
(anti-13).
Diisopropylethylamine (18 mL, 0.1 mmol, 0.1 equiv) was added via
syringe to a flame-dried, 5 mL, Schlenk flask under N2 containing a
solution of 42 mg (0.05 mmol, 0.05 equiv) of bis-phosphoramide
(R,R)-1 in CH2Cl2 (2 mL). To this solution was added 102 mL (1.0
mmol) of benzaldehyde in one portion. To the resulting solution
was added 172 mL (1.5 mmol, 1.5 equiv) of SiCl4 in one portion and
the reaction mixture was cooled to –72 °C over 15 min. Then, 224
mL (1.2 mmol, 1.2 equiv) of 12 was added dropwise over 1 min. The
resulting mixture was stirred at –72 °C for 2 h whereupon 3 mL of
chilled CH2Cl2 was added before the cold reaction mixture was
poured into a rapidly stirring solution of 1:1 sat. aq NaHCO3/sat. aq
KF (25 mL) at 0 °C. This biphasic mixture was stirred vigorously
for 1 h before being filtered through Celite. The phases were then
separated and the aqueous layer was washed with CH2Cl2 (3 × 40
mL). The combined organic extracts were dried over Na2SO4, fil-
tered and the filtrate was concentrated in vacuo. The residue was pu-
rified by column chromatography (silica gel, pentane–Et2O, 1:1) to
give 182 mg (90%) of (+)-137a as thick oil, which solidified upon
standing. Data for (anti-13): 1H NMR (500 MHz, CDCl3): d = 7.43–
7.32 (m, 5 H), 7.25 (dt, J = 10.3, 1.7 Hz, 1 H), 6.09 (dd, J = 10.3,
2.4 Hz, 1 H), 4.59 (dd, J = 7.8, 3.2 Hz, 1 H), 2.78–2.73 (m, 1 H),
2.49–2.21 (m, 1 H), 2.35–2.28 (m, 1 H), 2.03 (br s, 1 H), 1.75–1.68
(m, 2 H). 13C NMR (125 MHz, CDCl3): d = 199.95, 151.63, 142.17,
24
142.43, 130.17, 110.29, 107.47, 70.13, 41.49, 36.73, 25.40. [a]D
+58.18 (c = 1.05, EtOH). SFC: (4S,7S)-17 tR 5.77 min (18.5%);
(4R,7R)-17 tR 7.14 min (81.5%) (OJ column, 125 bar, 2.5 mL/min,
5.0% MeOH). Anal. Calcd for C11H12O3 (192.21): C, 68.74%; H,
6.29%. Found: C, 68.59%; H, 6.34%.
Acknowledgment
We are grateful for the National Science Foundation generous
financial support (NSF CHE0105205 and CHE0414440).
References
(1) Casiraghi, G.; Zanardi, F.; Appendino, G.; Rassu, G. Chem.
Rev. 2000, 100, 1929.
(2) (a) Evans, D. A.; Hu, E.; Burch, J. D.; Jaeschke, G. J. Am.
Chem. Soc. 2002, 124, 5654. (b) Paterson, I.; Davies, R. D.
M.; Heimann, A. C.; Marquez, R.; Meyer, A. Org. Lett.
2003, 5, 4477.
(3) Fettes, A.; Carreira, E. M. Angew. Chem. Int. Ed. 2002, 41,
4098.
(4) Hoveyda, A. H.; Evans, D. A.; Fu, G. C. Chem. Rev. 1993,
93, 1307.
(5) (a) Braun, M. Angew. Chem., Int. Ed. Engl. 1987, 26, 24.
(b) Nelson, S. G. Tetrahedron: Asymmetry 1998, 9, 357.
(c) Carreira, E. M. In Comprehensive Asymmetric Catalysis,
Vol. 3; Jacobsen, E. N.; Pfaltz, A.; Yamamoto, H., Eds.;
Springer-Verlag: Heidelberg, 1999. (d) Machjewski, T. D.;
Wong, C.-H. Angew. Chem. Int. Ed. 2000, 39, 1352.
24
129.83, 128.62, 128.142, 126.24, 76.54, 43.58, 36.74, 25.82. [a]D
+114.38 (c 1.00, EtOH). SFC: (4S,7S)-13 tR 6.52 min (2.5%);
(4R,7R)-13 tR 9.65 min (97.5%) (OJ column, 150 bar, 2.75 mL/min,
6.0% MeOH).
(+)-(4R,7R)-4-[Hydroxy-(1-naphthalenyl)methyl]-2-cyclo-
hexen-1-one (anti-15).
1H NMR (500 MHz, CDCl3): d = 8.12 (d, J = 8.3 Hz, 1 H), 7.91 (d,
J = 9.3 Hz, 1 H), 7.84 (d, J = 8.3 Hz, 1 H), 7.68 (d, J = 7.1 Hz, 1 H),
Synlett 2004, No. 13, 2411–2416 © Thieme Stuttgart · New York